Drug intelligence / Profile preview

auranofin + sirolimus

Development stage: Unknown
Lead developer: Mayo Clinic
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **auranofin**, a gold-containing compound traditionally used for rheumatoid arthritis, and **sirolimus**, an immunosuppressant that inhibits the mammalian target of rapamycin (mTOR). The combination is being explored for its potential in treating various cancers, including lung cancer and ovarian cancer, by modulating immune responses and inhibiting tumor growth.

Targets

TXNRD2 (Thioredoxin reductase 2)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on auranofin + sirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on auranofin + sirolimus.

Explore the full profile